About this Research Topic
In 2018, urologic cancers represented 22.6 % of cancer cases worldwide, with a rising incidence due to demographic trends such as population growth as well as aging. Urologic cancers comprise a wide range of solid tumors of different organs such as prostate, kidney and bladder cancer, which are common in elderly adults, but also testicular cancer being more prevalent in men of younger age. In the past decades, the understanding of dysregulated pathways and the identification of potential biomarkers for the treatment of urological cancers helped to identify new targets and pathways for novel-targeted therapies, including immunomodulatory agents and agents targeting angiogenesis, growth factor receptors, and epigenetic pathways. Besides being more effective, targeted approaches also aim to reduce the severe short- and long-term side effects known for conventional chemo- and radiotherapies.
Due to the well-known implications of targeted therapies in modulating tumorigenesis, many pathways have been explored as potential targets in urological cancers. The aim is to update the developmental status of targeted therapies in prostate, kidney, bladder and testicular cancer as well as to present clinical evidence on their single agent or combinational use. The articles of the Research Topic will help to highlight recent advances in the field and should be contributed as Original Research Articles or Reviews. Preclinical and clinical research is equally appreciated.
The manuscripts should be focused but are not only limited to:
· Targeted therapies and predictive biomarkers in urologic cancers cancer
· Novel therapeutic approaches for treatment of testicular cancer
· New molecular targets and pathways for renal cell carcinoma
· Animal models and model systems to study of novel treatments for urological cancers
· Predictive biomarkers for immunotherapy in urological cancers
· Imaging techniques to detect effects of therapies
· Molecular mechanisms of progression and invasion in urological cancers
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Due to the well-known implications of targeted therapies in modulating tumorigenesis, many pathways have been explored as potential targets in urological cancers. The aim is to update the developmental status of targeted therapies in prostate, kidney, bladder and testicular cancer as well as to present clinical evidence on their single agent or combinational use. The articles of the Research Topic will help to highlight recent advances in the field and should be contributed as Original Research Articles or Reviews. Preclinical and clinical research is equally appreciated.
The manuscripts should be focused but are not only limited to:
· Targeted therapies and predictive biomarkers in urologic cancers cancer
· Novel therapeutic approaches for treatment of testicular cancer
· New molecular targets and pathways for renal cell carcinoma
· Animal models and model systems to study of novel treatments for urological cancers
· Predictive biomarkers for immunotherapy in urological cancers
· Imaging techniques to detect effects of therapies
· Molecular mechanisms of progression and invasion in urological cancers
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
